Tailoring Gene Editing Therapies from Discovery through Preclinical Development Using Analytical Methods For Benchmarking Small CRISPR Cas Nucleases

Time: 4:15 pm
day: Day Two


  • Arbor is developing genetic medicines using a wholly owned portfolio of proprietary gene editing enzymes, including CRISPR cas nucleases with small sizes and unique properties that enable breakthrough applications.
  • Arbor nucleases are mined from metagenomes, engineered using a high-throughput pipeline, and optimized for activity in therapeutically relevant cellular contexts.
  • We will discuss analytical approaches for comparing nuclease activity spanning search, bacterial screening, mammalian cell screening, and preclinical, development.